Immunotherapy is now considered to be the key treatment for cancer, and the PD-1 checkpoint has achieved significant progress in clinical therapy for human melanoma, lung cancer, renal cancer, and Hodgkin's lymphoma (7). This evidence concerns the gene PDCD1 and lung carcinoma.